About Us
Oxford Brain Diagnostics (OBD) is advancing quantitative brain imaging to improve the assessment and treatment of neurodegenerative diseases. Built on two decades of research at the University of Oxford, its patented Cortical Disarray Measurement (CDM®) technology uses advanced MRI to measure subtle changes in brain microstructure that conventional MRI may not detect.
Its FDA-cleared CDM Insights® software provides quantitative insights to support disease detection, differential diagnosis, patient characterization, and ongoing monitoring. OBD also supports pharmaceutical and biotechnology companies by providing imaging biomarkers for clinical research and drug development.
With more than 40 scientific publications and collaborations across healthcare, academia, and the pharmaceutical industry, OBD aims to advance precision brain health through quantitative brain biology.
